News from neurovive pharmaceutical A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

21 May, 2019, 07:45 BST NeuroVive Pharmaceutical AB Interim Report January - March 2019

Important events January-March 2019 NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study. NeuroVive is supplied with approximately ...


10 May, 2019, 07:48 BST NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved...


25 Mar, 2019, 09:48 GMT NeuroVive Pharmaceutical AB Publishes 2018 Annual Report

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now...


19 Mar, 2019, 07:51 GMT NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company's KL1333 phase Ia/b ...


07 Mar, 2019, 08:07 GMT NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has successfully conducted a directed new issue...


21 Feb, 2019, 07:52 GMT NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license ...


15 Nov, 2018, 11:25 GMT NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders

NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche ...


31 Oct, 2018, 08:07 GMT NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1

NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) announces today that the subscription period ...


10 Oct, 2018, 07:41 BST NeuroVive Receives KL1333 Clinical Trial Regulatory Approval

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application...


04 Oct, 2018, 07:50 BST NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its ...


06 Sep, 2018, 07:57 BST NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its...


28 Aug, 2018, 08:03 BST NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that scientists at the company's research partner the Children's...


21 Aug, 2018, 08:15 BST NeuroVive Pharmaceutical AB Interim Report January - June 2018

Important events January-June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The...


18 Jun, 2018, 07:50 BST NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an...


31 May, 2018, 08:15 BST Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)

euroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of...


22 May, 2018, 08:00 BST NeuroVive Pharmaceutical AB Interim Report January - March 2018

Successful rights issue Business operations Important events January – March 2018 NeuroVive decided to conduct a rights issue for the continued...


21 May, 2018, 10:20 BST NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today...


02 May, 2018, 08:04 BST NeuroVive Initiates Collaboration With Leading US TBI Research Organization

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a partnership with TRACK-TBI, a network of US-based world-leading...


27 Apr, 2018, 13:31 BST Amendment: Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

euroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) ("NeuroVive") today on 27 April 2018 held its Annual General Meeting (AGM). A...


27 Apr, 2018, 11:33 BST Resolutions From Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) ("NeuroVive") today on 27 April 2018 held its Annual General Meeting (AGM). A...


27 Apr, 2018, 07:50 BST Preferential Rights Issue in NeuroVive Oversubscribed

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND,...


20 Apr, 2018, 10:42 BST NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that its mitochondrial myopathy project, NVP025, has been selected ...


20 Apr, 2018, 07:57 BST NeuroVive's Board Members, Senior Executives and Employees Will Subscribe Units in the Ongoing Rights Issue

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 191,200 units...


18 Apr, 2018, 08:39 BST NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases

euroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted...


17 Apr, 2018, 07:52 BST NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today...